Advancing Early Alzheimer’s Detection with LucentAD® Complete

LucentAD® Complete is a blood-based test that helps detect Alzheimer’s disease early using multiple biomarkers and a proprietary algorithm. Powered by Simoa® technology, it offers a non-invasive, accessible alternative to traditional methods. Available as an LDT, it supports clinical decision-making and streamlines trial recruitment by identifying individuals in early stages.

Key Points

• LucentAD® Complete enables early Alzheimer’s detection using blood-based biomarkers.
• The test uses Simoa® technology and a proprietary algorithm for accurate results.
• It offers a non-invasive, accessible alternative to PET scans and CSF analysis.
• It aids clinical trials by identifying early-stage participants for new therapies.
• Available as an LDT, it supports immediate clinical decision-making and referrals.

Alzheimer’s disease remains a growing global health crisis, with nearly 7 million Americans currently living with the disease—a figure expected to double by 2050. As the population ages and new therapies like Leqembi and Kisunla gain approval for early-stage intervention, the demand for practical, accessible diagnostic tools has never been more urgent. Traditional diagnostic methods, such as positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) analysis, remain effective but are often costly, invasive and logistically challenging.

LucentAD® Complete is a multi-analyte, algorithmic blood test designed to provide clinicians with a practical, non-invasive tool for assessing Alzheimer’s risk with high diagnostic accuracy. Powered by Quanterix’s Simoa® HD-X technology, LucentAD® Complete combines biomarkers including p-Tau 217, Aß40, Aß42, GFAP and NfL through a proprietary algorithm to deliver precise and actionable insights.

Available today as a laboratory-developed test (LDT), LucentAD® Complete offers clinicians immediate access to its capabilities. This accessibility is particularly valuable in clinical environments where early intervention can significantly impact patient outcomes. From primary care settings to specialised neurology practices, the test provides actionable insights that can guide clinical decision-making and streamline patient referrals for advanced diagnostic evaluation.

Beyond routine clinical use, LucentAD® Complete is also proving invaluable in clinical research settings, particularly for the recruitment and stratification of participants in Alzheimer’s clinical trials. Therapies targeting the earliest stages of Alzheimer’s disease require diagnostic tools capable of identifying potential trial candidates early enough to achieve meaningful therapeutic benefit. Traditional diagnostics, while effective, are often impractical for large-scale screening due to their invasiveness, expense and logistical challenges.

LucentAD® Complete addresses these limitations by offering a scalable, blood-based alternative that can be readily integrated into clinical trials. Its ability to accurately identify amyloid-positive individuals early in the disease process supports more efficient patient selection and enhances data quality. For researchers evaluating new therapies aimed at slowing or halting Alzheimer’s progression, the availability of a reliable diagnostic tool that can be deployed widely is essential.

Although Quanterix is actively pursuing FDA approval for the underlying technology, LucentAD® Complete is already delivering value to clinicians and researchers today. Its immediate availability provides a much-needed resource for those working to address Alzheimer’s disease at its earliest stages.

To gain a deeper understanding of LucentAD® Complete’s clinical utility, applications and analytical validation, download the full white paper at LucentDiagnostics.com.

Conflict of Interest

Spotlight articles are the sole opinion of the author(s), and they are part of the HealthManagement.org Corporate Engagement or Educational Community Programme.